ATRC vs. TFX, ITGR, ATEC, IART, OFIX, SRDX, ANGO, ARAY, RMTI, and RSLS
Should you be buying AtriCure stock or one of its competitors? The main competitors of AtriCure include Teleflex (TFX), Integer (ITGR), Alphatec (ATEC), Integra LifeSciences (IART), Orthofix Medical (OFIX), Surmodics (SRDX), AngioDynamics (ANGO), Accuray (ARAY), Rockwell Medical (RMTI), and ReShape Lifesciences (RSLS). These companies are all part of the "health care equipment" industry.
AtriCure vs. Its Competitors
Teleflex (NYSE:TFX) and AtriCure (NASDAQ:ATRC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.
Teleflex has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.
In the previous week, Teleflex had 9 more articles in the media than AtriCure. MarketBeat recorded 12 mentions for Teleflex and 3 mentions for AtriCure. Teleflex's average media sentiment score of 0.76 beat AtriCure's score of 0.38 indicating that Teleflex is being referred to more favorably in the media.
Teleflex has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500.
Teleflex has a net margin of 4.96% compared to AtriCure's net margin of -7.95%. Teleflex's return on equity of 14.73% beat AtriCure's return on equity.
95.6% of Teleflex shares are held by institutional investors. Comparatively, 99.1% of AtriCure shares are held by institutional investors. 1.4% of Teleflex shares are held by company insiders. Comparatively, 3.5% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Teleflex currently has a consensus target price of $159.63, suggesting a potential upside of 40.84%. AtriCure has a consensus target price of $50.67, suggesting a potential upside of 66.75%. Given AtriCure's stronger consensus rating and higher probable upside, analysts plainly believe AtriCure is more favorable than Teleflex.
Summary
Teleflex beats AtriCure on 9 of the 16 factors compared between the two stocks.
Get AtriCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ATRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AtriCure Competitors List
Related Companies and Tools
This page (NASDAQ:ATRC) was last updated on 7/16/2025 by MarketBeat.com Staff
Free ATRC Stock Alerts